Navigation Links
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Date:8/6/2009

rd quarter; and finally, our plans to present the results of all seven cohorts of the INFORM-1 study at the AASLD meeting on November 3."

Results for the Three Months Ended June 30, 2009

InterMune reported total revenue in the second quarter of 2009 of $7.9 million, compared with total revenue of $8.1 million in the second quarter of 2008. Total revenue in the second quarter of 2009 primarily consisted of Actimmune(R) (interferon gamma-1b) revenue of $7.1 million, compared with $7.3 million in the same quarter of 2008, a decrease of approximately 2 percent, reflecting lower off-label physician prescriptions of Actimmune for the treatment of idiopathic pulmonary fibrosis (IPF), which InterMune does not promote.

Research and development (R&D) expenses in the second quarter of 2009 were $22.9 million compared with $25.4 million in the second quarter of 2008, a decrease of approximately 10 percent, reflecting completion of the CAPACITY clinical trials in early 2009, partially offset by expenses associated with the RECAP extension study and the preparation of the NDA and MAA for pirfenidone. General and administrative (G&A) expenses were $8.5 million in the second quarter of 2009, compared with $7.1 million in the same period a year earlier, an increase of approximately 20 percent, primarily attributed to costs related to preparation for the anticipated commercialization of pirfenidone.

InterMune recorded a loss on extinguishment of debt of $9.5 million, of which $8.9 million was non-cash, in the second quarter of 2009 in connection with the April 2009 exchange of approximately $32.3 million of its 0.25% Convertible Senior Notes due 2011 held by certain of its debt holders for shares of the company's common stock. A total of approximately 2.1 million shares of common stock were issued in connection with the transaction.

As of June 30, 2009, InterMune had cash, cash e
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. InterMune to Release Second Quarter Financial Results on August 6
2. InterMune to Present at Goldman Sachs Healthcare Conference
3. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
4. InterMune to Release First Quarter Financial Results on April 30
5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
6. InterMune to Present at Canaccord Adams Hepatitis C Conference
7. InterMune to Present at Citis 4th Annual Biotech Day
8. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
9. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
10. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... (PRWEB) October 02, 2014 Protea ... AG jointly announced today an update from their ... 3D InSight™ microtissues. In August 2014, Protea received ... scientific team for onsite training on the handling ... developed workflows for processing the 3D microtissues for ...
(Date:10/2/2014)... Wayne, NJ (PRWEB) October 02, 2014 At ... squeezed, Bel-Art Products has introduced a new kind ... New to market is the Scienceware® Squeeze Rite™ Wash ... the dip tube position within the bottle reduces the waste ... complete dispensing of those liquids. , “Easier to squeeze when ...
(Date:10/2/2014)... 2, 2014  CSSi ( www.CSSiEnroll.com ), the ... research industry, is pleased to announce its participation ... of October.  President Chris Trizna will ... in Clinical Trials New England conference sponsored by ... the annual Site Solutions Summit sponsored by the ...
(Date:10/2/2014)... and BRIDGEWATER, N.J. , Oct. 2, ... a leader in synthetic biology, and Amneal ... manufacturer by volume in the U.S., today announced ... (ECC) for a target active pharmaceutical ingredient (API).  ... of the collaboration is to develop a consistent, ...
Breaking Biology Technology:Protea Biosciences and InSphero AG Successful in Mass Spectrometry Imaging of 3D Microtissues 2Protea Biosciences and InSphero AG Successful in Mass Spectrometry Imaging of 3D Microtissues 3Protea Biosciences and InSphero AG Successful in Mass Spectrometry Imaging of 3D Microtissues 4New Wash Bottle Reduces Waste of Reagents, Solutions, and Other Liquids 2Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 2Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 3Intrexon and Amneal Expand Relationship with Second Product Collaboration 2Intrexon and Amneal Expand Relationship with Second Product Collaboration 3
... Aug. 28 Medivation, Inc.,(Nasdaq: MDVN ) today ... will present at the following conferences:, -- BioCentury,s ... 9:00 a.m. Eastern Time at the Millennium Broadway Hotel ... Conference on Wednesday, September 24,at 4:30 p.m. Eastern Time ...
... Exclusion of Venous Thromboembolism-, LEXINGTON, Mass., Aug. ... US Food and Drug Administration (FDA) has,granted 510(k) ... HemosIL D-Dimer,assay to exclude venous thromboembolism (VTE) in ... embolism (PE), when used in,conjunction with a clinical ...
... (ESA) has appointed the UK,s National Physical Laboratory (NPL) ... will lead a consortium to identify the next generation ... in future space missions. , "Advances in nanotechnology are ... Research Scientist in the nanomaterials group at NPL, who ...
Cached Biology Technology:Medivation Announces Participation in Upcoming Conferences 2Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use of HemosIL(R) D-Dimer Assay 2
(Date:9/30/2014)... captured the popular attention of both children and aquarium ... sold as dehydrated eggs, these tiny brine shrimp readily ... tank of salt water. , Physicists, though, are ... shrimp vertically migrate in large groups in response to ... night and retreating deeper during the day. , Two ...
(Date:9/30/2014)... Prenatal exposure to tetrachloroethylene (PCE) in drinking water ... abruption, according to a new study led by ... , The study, published in the journal ... 1,019 unexposed pregnancies among 1,766 women in Cape ... late 1960s to the early 1980s by the ...
(Date:9/30/2014)... runoff in Hawaii is causing tumors in endangered sea ... published Tuesday in the peer-reviewed open-access journal PeerJ ... in algae that the turtles eat, promoting the formation ... organs. , Scientists at Duke University, the University of ... conducted the study to better understand the causes ...
Breaking Biology News(10 mins):Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Contaminated water linked to pregnancy complications, BU study finds 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3
... Autism Speaks applauds the consensus statement and recommendations ... disorders in children with autism spectrum disorders (ASD) released ... advancing physician awareness of unique challenges in the medical ... see the publication of these consensus recommendations. Autism Speaks, ...
... nerves are the likely origin of the Devil Facial Tumour ... an international team of scientists has discovered. Devil ... only Tasmanian devils and was first reported in 1996. It ... disease is characterised by large tumours, mostly on the face ...
... have new insight into the sex lives of the much-maligned ... deaths, according to a report published online on December 31st ... finding a partner of the right species type, male and ... harmony. Those tones are produced and varied based on the ...
Cached Biology News:Pediatrics GI recommendations -- first step to guidelines for children with autism 2Pediatrics GI recommendations -- first step to guidelines for children with autism 3Nervous culprit found for Tassie devil facial tumor disease 2To a mosquito, matchmaking means 'singing' in perfect harmony 2
Melanoma Antigen, Family C, 1 (MAGEC1) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: New Recommended Storage: Long term: -20C; Short term: +4...
X box-binding protein 1...
Mouse monoclonal [AE3] to Cytokeratin 1 - 8, prediluted ( Abpromise for all tested applications). Antigen: Tissue / cell preparation - Human epidermal cells. Entrez GeneID: 140807 Swiss P...
Mouse HAI-1 Ectodomain MAb (Clone 199732)...
Biology Products: